Antisense IRAK-2 oligodeoxynucleotide inhibits interleukin-1-induced nuclear factor-kappa B activation in vitro.
OBJECTIVE
To study the inhibitory effects of antisense interleukin-1 receptor associated kinase-2 (IRAK-2) oligodeoxynucleotide (ODN) on interleukin-1 (IL-1)-stimulated nuclear factor-kappa B (NF-kappa B) activation.


METHODS
Antisense IRAK-2 ODN was delivered by lipofectin encapsulation into human embryonic kidney 293 cells (HEK 293 cells). The levels of NF-kappa B were assayed by sandwich ELISA.


RESULTS
(1) Treatment of HEK 293 cells with IL-1 enhanced NF-kappa B level in nuclei by 518.5% +/- 2.1%. (2) Antisense IRAK-2 ODN inhibited IL-1-induced NF-kappa B activation in a concentration (1-8 micrograms)- and time (5-24 h)-dependent manner. A maximum inhibition was 70.7% +/- 1.0% from Acontrol 0.834 +/- 0.014 to 0.244 +/- 0.008 after treatment with antisense IRAK-2 ODN 4 micrograms for 8 h.


CONCLUSIONS
Antisense IRAK-2 ODN inhibited IL-1-induced NF-kappa B activation.
Guo
F K
FK
Institute of Pharmaceutic Sciences, First Military Medical University, Guangzhou 510515, China.
Li
Y L
YL
Wu
S G
SG
D002478:Cells, Cultured; D004622:Embryo, Mammalian; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D053592:Interleukin-1 Receptor-Associated Kinases; D007668:Kidney / Q000166:cytology*; D016328:NF-kappa B / Q000378:metabolism*; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology*; D011494:Protein Kinases / Q000494:pharmacology*; D014162:Transfection
D007375:Interleukin-1; D016328:NF-kappa B; D020319:Oligodeoxyribonucleotides, Antisense; D011494:Protein Kinases; D053592:Interleukin-1 Receptor-Associated Kinases